RSV vaccine safety in pregnancy: new study looks at side effects for moms and infants
NCT ID NCT06482099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in Japan checked the safety of the RSV vaccine Abrysvo in 497 pregnant women and their infants. Researchers tracked side effects in mothers for 28 days after vaccination and in babies from birth to 28 days old. The goal was to confirm the vaccine's safety in real-world use, not to measure how well it prevents infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abrysvo (RSVpreF vaccine)
- What this could lead to
- If safety is confirmed, this could support the use of the RSV vaccine during pregnancy to protect newborns from severe RSV infection.
- What could go wrong
- This is a safety-only study with no efficacy results. It was small (497 participants) and conducted only in Japan, so findings may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.